Clinical Trial Detail

NCT ID NCT04338269
Title A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

papillary renal cell carcinoma

renal cell carcinoma

clear cell renal cell carcinoma

Therapies

Cabozantinib

Atezolizumab + Cabozantinib

Age Groups: senior adult

No variant requirements are available.